Mission

Innovative NeuroTechnologies, Inc. (INT) is a discovery-stage biotechnology company that seeks diagnostic and therapeutic solutions to major human central nervous system (CNS) disorders, particularly in the area of neurodegeneration. The Company focuses its efforts on such diseases

These are typically fatal neurodegenerative disorders that are currently untreatable and share many characteristics, which make them particularly amenable to INT's expertise and employed technologies.


Since its founding in March 2005, INT has engaged in complex, state-of-the-art high-throughput genomic, proteomic, and bioinformatic-based technologies to identify novel biomarkers (e.g., nucleic acids, proteins, and/or metabolites) for the development of new highly predictive, reliable, and accurate early detection assays and therapeutic agents (i.e., drug discovery) for major CNS disorders. INT’s unique technologies measure and assess neurodegenerative processes at work – at the molecular, cellular, and macroscopic levels – and are ideally suited to identify the earliest evidence of pathology in models of human diseases of the CNS. The Company dedicates these technologies to the discovery and development of therapeutic agents to provide effective treatments for diseases characterized by neurodegeneration.


This approach, commonly referred to as Systems Biology, represents a paradigm-shift in biology where an organism is viewed as an integrated and interacting network of genes, proteins, and biochemical reactions that give rise to life. The Systems Biology approach symbolizes a revolution in future healthcare in which medicine will no longer be reactive with a focus on developing therapies for preexisting diseases, but predictive and preventive. In the near future, individuals will have relevant portions of their genomes sequenced, and multiparameter diagnostic assays, based on sensitive and early detection of disease biomarkers, will become a standard procedure for evaluating each individual’s current and future health and disease status.


Due to its predictive and preventive nature, the Systems Biology approach naturally leads to personalized medicine (i.e., pharmacogenomics). Modern pharmacogenomic techniques have already rapidly accelerated disease associated gene discovery, which in turn has dramatically increased the pace that novel drug compounds are developed. The application of these technologies enable the development of novel therapeutics “custom tailored” to an individual’s genetic make-up, which allows drug compounds to be designed with minimal damaging effects and maximal efficiency.


In addition, current methodologies from the fields of nanotechnology, such as quantum dot nanocrystals and microfluidics, and molecular imaging can further be implemented and integrated within the overall Systems Biology framework, which in turn gives rise to the view of NanoSystems Biology.


INT’s mission is to employ innovative technologies based on the NanoSystems Biology approach to discover and develop novel highly sensitive molecular diagnostic assays and blockbuster therapeutic agents for the treatment of major CNS diseases through cutting-edge research funded by strategic investors and partners and ongoing service revenues.